| Title: |
Cytokines as new treatment targets in chronic heart failure |
| Authors: |
Gullestad Lars; Damås Jan; Aukrust Pål |
| Source: |
Current Controlled Trials in Cardiovascular Medicine, Vol 2, Iss 6, Pp 271-277 (2001) |
| Publisher Information: |
BMC, 2001. |
| Publication Year: |
2001 |
| Collection: |
LCC:Medicine (General) |
| Subject Terms: |
chronic heart failure; cytokines; immunomodulating therapy; intravenous immunoglobulin; Medicine (General); R5-920 |
| Description: |
Abstract Inflammatory cytokines may negatively influence contractility and contribute to the remodelling process in the failing myocardium. Traditional cardiovascular drugs appear to have little influence on the overall cytokine network in chronic heart failure (CHF). Increased interest in anticytokine therapy has therefore evolved. Several small studies have used tumour necrosis factor (TNF)-α as a target, resulting in improved functional capacity and myocardial performance. Intravenous immunoglobulin (IVIG) represents another therapeutic approach in which the impact on myocardial performance appears to be correlated with anti-inflammatory effects. These studies demonstrate potential for immunomodulation as a therapy in addition to conventional cardiovascular treatment in CHF, but the most effective drugs in this regard have yet to be identified. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1468-6708 |
| Relation: |
https://doaj.org/toc/1468-6708 |
| DOI: |
10.1186/cvm-2-6-271 |
| Access URL: |
https://doaj.org/article/4f0176f9cfd8453090643d64bbf686e5 |
| Accession Number: |
edsdoj.4f0176f9cfd8453090643d64bbf686e5 |
| Database: |
Directory of Open Access Journals |